CN115667296A8 - 抗fam19a1拮抗剂用于治疗中枢神经系统疾病的用途 - Google Patents

抗fam19a1拮抗剂用于治疗中枢神经系统疾病的用途 Download PDF

Info

Publication number
CN115667296A8
CN115667296A8 CN202180026331.0A CN202180026331A CN115667296A8 CN 115667296 A8 CN115667296 A8 CN 115667296A8 CN 202180026331 A CN202180026331 A CN 202180026331A CN 115667296 A8 CN115667296 A8 CN 115667296A8
Authority
CN
China
Prior art keywords
antagonists
nervous system
central nervous
fam
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180026331.0A
Other languages
English (en)
Other versions
CN115667296A (zh
Inventor
金峰彻
金东植
权纯玖
河昵
成在英
黄钟益
龙效定
赵恩妃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea University Research and Business Foundation
Original Assignee
Korea University Research and Business Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea University Research and Business Foundation filed Critical Korea University Research and Business Foundation
Publication of CN115667296A publication Critical patent/CN115667296A/zh
Publication of CN115667296A8 publication Critical patent/CN115667296A8/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Environmental Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)

Abstract

本公开涉及一种治疗中枢神经系统(CNS)功能异常相关的疾病或紊乱的方法。还提供了一种诊断和/或鉴定具有CNS功能异常的受试者的方法。还提供了可与本公开一起使用的FAM19A1拮抗剂。
CN202180026331.0A 2020-03-02 2021-03-02 抗fam19a1拮抗剂用于治疗中枢神经系统疾病的用途 Pending CN115667296A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062984166P 2020-03-02 2020-03-02
US62/984,166 2020-03-02
PCT/IB2021/051704 WO2021176336A1 (en) 2020-03-02 2021-03-02 Use of anti-fam19a1 antagonists for treating central nervous system diseases

Publications (2)

Publication Number Publication Date
CN115667296A CN115667296A (zh) 2023-01-31
CN115667296A8 true CN115667296A8 (zh) 2023-08-29

Family

ID=77612893

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180026331.0A Pending CN115667296A (zh) 2020-03-02 2021-03-02 抗fam19a1拮抗剂用于治疗中枢神经系统疾病的用途

Country Status (6)

Country Link
US (1) US20230104540A1 (zh)
EP (1) EP4114855A4 (zh)
JP (2) JP2023516992A (zh)
KR (1) KR20220143786A (zh)
CN (1) CN115667296A (zh)
WO (1) WO2021176336A1 (zh)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013122408A1 (ko) * 2012-02-15 2013-08-22 고려대학교 산학협력단 신경교세포 생성 조절에 관여하는 fam19a5의 약제학적 용도
JP7045724B2 (ja) * 2016-11-07 2022-04-01 ニューラクル サイエンス カンパニー リミテッド 配列類似性を持つ抗ファミリー１９、メンバーａ５抗体及びその用途
KR102574549B1 (ko) * 2017-06-27 2023-09-07 주식회사 뉴라클사이언스 항-fam19a5 항체 및 이의 용도
CN110386973B (zh) * 2018-04-18 2022-09-27 北京大学 具有多种功能的蛋白多肽及其医药用途
JP7171081B2 (ja) * 2018-04-24 2022-11-15 ニューラクル サイエンス カンパニー リミテッド 神経病性疼痛の治療のための配列類似性１９、メンバーａ５抗体を有する抗ファミリーの用途

Also Published As

Publication number Publication date
EP4114855A4 (en) 2024-04-03
JP2024016199A (ja) 2024-02-06
KR20220143786A (ko) 2022-10-25
CN115667296A (zh) 2023-01-31
JP2023516992A (ja) 2023-04-21
US20230104540A1 (en) 2023-04-06
EP4114855A1 (en) 2023-01-11
WO2021176336A1 (en) 2021-09-10

Similar Documents

Publication Publication Date Title
Michiels et al. Does multi-modal cervical physical therapy improve tinnitus in patients with cervicogenic somatic tinnitus?
Cordeau Monorhythmic frontal delta activity in the human electroencephalogram: a study of 100 cases
Dahl et al. Effects of a broad‐spectrum behavior modification treatment program on children with refractory epileptic seizures
Jaracz et al. Consequences of stroke in the light of objective and subjective indices: a review of recent literature
CN115667296A8 (zh) 抗fam19a1拮抗剂用于治疗中枢神经系统疾病的用途
MX2021010467A (es) Biomarcadores para dolencias articulares y usos de estos.
Bakhshipour et al. Investigating the effect of mindfulness-based cognitive therapy (MBCT) on depression, quality of life, and anxiety in MS patients
Fuller et al. Sadistic and self‐defeating personality disorder criteria in a rural clinic sample
Chuprina Multiple sclerosis: etiology, pathogenesis, clinic, diagnosis, differential diagnosis, treatment (clinical lecture)
Gervasio et al. Exploring the EEG signatures of musculoskeletal pain
Elsayed et al. Factors Affecting Return of Stroke Patients to Their Job.
DE425205C (de) Riffelzylinder fuer Streckwerke
Nicholls et al. Special workshop on repeated and late reactions
Kucherenko et al. Distribution of vegetative dysfunctions and depressive positions among sexually active students and students without sexual debut of National Pirogov Memorial Medical University, Vinnytsya
Beer Examining FYCO1 as a modulator of autophagy for alpha-synuclein aggregate clearance in hiPSC derived neurons
Otaiku 026 Impulse control disorders in idiopathic REM sleep behaviour disorder and drug-naive Parkinson’s disease
DE503041C (de) Vorrichtung zum pendelnden Aufhaengen von elektrischen Apparaten, namentlich von auf Fahrzeugen eingebauten Gleichrichtern
Karnasih et al. AB069. Type of personality and cancer-related pain in central nervous system (CNS) tumor patients: a cross-sectional study
Dharmadasa et al. 10. phenotypic variability in motor neuron disease: site of onset and patterns of disease spread
Park et al. The Relationships between Caregiver Burden, Post-Traumatic Growth and Resilience among Mothers of Children with Developmental Disabilities
Satari et al. A study of sympathetic skin response in burns with different mechanisms
DE695304C (de) Zur Abstuetzung umlaufender Roest-, Sieb-, Mischtrommeln u. dgl. dienende Laufrolle
DE202018005160U1 (de) Snowboard Umbau Set - BoarderSledge
DE409140C (de) Leitungsstuetze fuer Kranschleifleitungen
DE202019000605U1 (de) Die Lebensleistung digitalisieren und weiter verwerten

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CI02 Correction of invention patent application
CI02 Correction of invention patent application

Correction item: Inventor

Correct: Jin Fengche|Jin Dongzhi|Quan Chunjiu|Heni|Cheng Zaiying|Huang Zhongyi|Long Xiaoding|Zhao Enfei

False: Jin Fengche|Jin Dongzhi|Quan Chunjiu|river|Cheng Zaiying|Huang Zhongyi|Long Xiaoding|Zhao Enfei

Number: 05-01

Page: The title page

Volume: 39

Correction item: Inventor

Correct: Jin Fengche|Jin Dongzhi|Quan Chunjiu|Heni|Cheng Zaiying|Huang Zhongyi|Long Xiaoding|Zhao Enfei

False: Jin Fengche|Jin Dongzhi|Quan Chunjiu|river|Cheng Zaiying|Huang Zhongyi|Long Xiaoding|Zhao Enfei

Number: 05-01

Volume: 39